<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.1 20050630//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id><journal-title>Nucleic Acids Research</journal-title><issn pub-type="ppub">0305-1048</issn><issn pub-type="epub">1362-4962</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">gke653</article-id><article-id pub-id-type="pmid">11812818</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Retinoic acid receptor &#x003b1;1 variants, RAR&#x003b1;1&#x00394;B and RAR&#x003b1;1&#x00394;BC, define a new class of nuclear receptor isoforms</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Parrado</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">1</xref><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">2</xref><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">3</xref><xref ref-type="author-notes" rid="N0x8bce9e0.0x8bffbb8">a</xref></contrib><contrib contrib-type="author"><name><surname>Despouy</surname><given-names>Gilles</given-names></name><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">1</xref></contrib><contrib contrib-type="author"><name><surname>Kra&#x000ef;ba</surname><given-names>Radhia</given-names></name><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">1</xref></contrib><contrib contrib-type="author"><name><surname>Pogam</surname><given-names>Carole Le</given-names></name><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">1</xref></contrib><contrib contrib-type="author"><name><surname>Dupas</surname><given-names>St&#x000e9;phane</given-names></name><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">1</xref><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">2</xref></contrib><contrib contrib-type="author"><name><surname>Choquette</surname><given-names>Maryline</given-names></name><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">1</xref></contrib><contrib contrib-type="author"><name><surname>Robledo</surname><given-names>Macarena</given-names></name><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">1</xref><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">2</xref></contrib><contrib contrib-type="author"><name><surname>Larghero</surname><given-names>J&#x000e9;r&#x000f4;me</given-names></name><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">1</xref></contrib><contrib contrib-type="author"><name><surname>Bui</surname><given-names>Hung</given-names></name><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">4</xref></contrib><contrib contrib-type="author"><name><surname>Gall</surname><given-names>Isabelle Le</given-names></name><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">4</xref></contrib><contrib contrib-type="author"><name><surname>Rochette-Egly</surname><given-names>C&#x000e9;cile</given-names></name><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">5</xref></contrib><contrib contrib-type="author"><name><surname>Chomienne</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">1</xref></contrib><contrib contrib-type="author"><name><surname>Padua</surname><given-names>Rose Ann</given-names></name><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">1</xref><xref ref-type="aff" rid="N0x8bce9e0.0x8c001d8">2</xref></contrib></contrib-group><aff id="N0x8bce9e0.0x8c001d8"><label>1</label>Laboratoire de Biologie Cellulaire H&#x000e9;matopo&#x000ef;&#x000e9;tique, INSERM U00-03, Universit&#x000e9; D. Diderot&#x02013;Paris VII, Institut d&#x02019;H&#x000e9;matologie, H&#x000f4;pital Saint-Louis, Paris, France, <label>2</label>Department of Haematology, University of Wales College of Medicine, Cardiff, UK, <label>3</label>Secci&#x000f3;n de Inmunolog&#x000ed;a, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, <label>4</label>Fondation Jean Dausset&#x02013;CEPH, H&#x000f4;pital Saint-Louis, Paris, France and <label>5</label>Institut de G&#x000e9;n&#x000e9;tique et de Biologie Mol&#x000e9;culaire et Cellulaire, Illkirch, France</aff><author-notes><fn id="N0x8bce9e0.0x8bffbb8"><label>a</label><p>To whom correspondence should be addressed at: Secci&#x000f3;n de Inmunolog&#x000ed;a, Hospital Universitario Virgen de la Arrixaca, El Palmar 30120, Murcia, Spain. Tel: &#x0002b;34 968 36 95 99; Fax: &#x0002b;34 968 36 96 78; Email: aparrado&#x00040;ono.com</p></fn></author-notes><pub-date pub-type="ppub"><day>15</day><month>12</month><year>2001</year></pub-date><volume>29</volume><issue>24</issue><fpage>4901</fpage><lpage>4908</lpage><ext-link ext-link-type="uri" xlink:href="http:&#x0002f;&#x0002f;www.nar.oupjournals.org&#x0002f;content&#x0002f;vol29&#x0002f;issue24&#x0002f;"/><history><date date-type="received"><day>1</day><month>10</month><year>2001</year></date><date date-type="accepted"><day>22</day><month>10</month><year>2001</year></date></history><copyright-statement>Copyright &#x000a9; 2001 Oxford University Press</copyright-statement><copyright-year>2001</copyright-year><abstract><p>Retinoic acid (RA) binds and activates retinoid X receptor (RXR)&#x0002f;retinoic acid receptor (RAR) heterodimers, which regulate the transcription of genes that have retinoic acid response elements (RARE). The RAR isotypes (&#x003b1;, &#x003b2; and &#x003b3;) are comprised of six regions designated A&#x02013;F. Two isoforms of RAR&#x003b1;, 1 and 2, have been identified in humans, which have different A regions generated by differential promoter usage and alternative splicing. We have isolated two new splice variants of RAR&#x003b1;1 from human B lymphocytes. In one of these variants, exon 2 is juxtaposed to exon 5, resulting in an altered reading frame and a stop codon. This variant, designated RAR&#x003b1;1&#x00394;B, does not code for a functional receptor. In the second variant, exon 2 is juxtaposed to exon 6, maintaining the reading frame. This isoform, designated RAR&#x003b1;1&#x00394;BC, retains most of the functional domains of RAR&#x003b1;1, but omits the transactivation domain AF-1 and the DNA-binding domain. Consequently, it does not bind nor transactivate RARE on its own. Nevertheless, RAR&#x003b1;1&#x00394;BC interacts with RXR&#x003b1; and, as an RXR&#x003b1;&#x0002f;RAR&#x003b1;1&#x00394;BC heterodimer, transactivates the DR5 RARE upon all-<italic>trans</italic>-RA binding. The use of RAR- and RXR-specific ligands shows that, whereas transactivation of the DR5 RARE through the RXR&#x003b1;&#x0002f;RAR&#x003b1;1 heterodimer is mediated only by RAR ligands, transactivation through the RXR&#x003b1;&#x0002f;RAR&#x003b1;1&#x00394;BC heterodimer is mediated by RAR and RXR ligands. Whilst RAR&#x003b1;1 has a broad tissue distribution, RAR&#x003b1;1&#x00394;BC has a more heterogeneous distribution, but with significant expression in myeloid cells. RAR&#x003b1;1&#x00394;BC is an infrequent example of a functional nuclear receptor which deletes the DNA-binding domain.</p></abstract></article-meta></front><body><sec><title>INTRODUCTION</title><p>Retinoic acid (RA) regulates the growth and differentiation of a wide variety of embryonic and adult cell types (<xref ref-type="bibr" rid="gke653c1">1</xref>, and references therein). Two classes of receptors bind RA, the retinoic acid receptors (RAR) and the retinoic X receptors (RXR). They belong to the superfamily of steroid-thyroid nuclear hormone receptors (<xref ref-type="bibr" rid="gke653c2">2</xref>). The known ligands for the RARs are all-<italic>trans</italic>-RA (ATRA) and 9-<italic>cis</italic>-RA and for the RXRs 9-<italic>cis</italic>-RA only (<xref ref-type="bibr" rid="gke653c3">3</xref>&#x02013;<xref ref-type="bibr" rid="gke653c5">5</xref>). Each class of receptor is composed of three genes, named &#x003b1;, &#x003b2; and &#x003b3; (<xref ref-type="bibr" rid="gke653c6">6</xref>&#x02013;<xref ref-type="bibr" rid="gke653c8">8</xref>). Based on sequence homology, the nuclear receptors are structured in modules. The RARs are composed of six regions, A&#x02013;F (Fig. <xref ref-type="fig" rid="gke653f1">1</xref>A and C), and the RXRs of five regions, A&#x02013;E. The A and B regions possess a promoter-specific, ligand-independent transcription activating function (AF-1) (<xref ref-type="bibr" rid="gke653c9">9</xref>). The C region constitutes the DNA-binding domain, through which the RARs bind to retinoic acid response elements (RARE), which are specific DNA sequences generally located in the vicinity of target genes. RAREs consist of direct repeats of the consensus sequence (A,G)G(T,G)TCA separated by 1&#x02013;5 nt (DR1-5) (<xref ref-type="bibr" rid="gke653c10">10</xref>&#x02013;<xref ref-type="bibr" rid="gke653c13">13</xref>). RARs bind to RAREs as heterodimers with RXRs. The E region contains the ligand-binding domain, a dimerization interface, the ligand-dependent transcription activating function (AF-2) and the corepressor binding and the coactivator association domains (<xref ref-type="bibr" rid="gke653c9">9</xref>,<xref ref-type="bibr" rid="gke653c14">14</xref>,<xref ref-type="bibr" rid="gke653c15">15</xref>).</p><p>The physiological effects of RA are mediated through activated RXR&#x0002f;RAR heterodimers that stimulate gene transcription (<xref ref-type="bibr" rid="gke653c16">16</xref>). In the absence of RA, RXR&#x0002f;RAR binds the nuclear receptor corepressor (N-CoR) or its homolog SMRT, which recruit histone deacetylase leading to transcriptional repression of target genes (reviewed in <xref ref-type="bibr" rid="gke653c15">15</xref>,<xref ref-type="bibr" rid="gke653c17">17</xref>). RA binding to RXR&#x0002f;RAR induces dissociation of corepressors, enabling the heterodimer to associate with nuclear receptor coactivator complexes, which include various histone acetyltransferases (<xref ref-type="bibr" rid="gke653c15">15</xref>,<xref ref-type="bibr" rid="gke653c17">17</xref>,<xref ref-type="bibr" rid="gke653c18">18</xref>). These data indicate that RARE-bound, RA-activated RXR&#x0002f;RAR heterodimers recruit the transcriptional apparatus to RARE-containing genes.</p><p>Seven isoforms of RAR&#x003b1; (RAR&#x003b1;1&#x02013;7), four of RAR&#x003b2; (RAR&#x003b2;1&#x02013;4) and seven of RAR&#x003b3; (RAR&#x003b3;1&#x02013;7) have been identified in mice (<xref ref-type="bibr" rid="gke653c19">19</xref>&#x02013;<xref ref-type="bibr" rid="gke653c23">23</xref>). The isoforms differ in their 5&#x02032;-untranslated region (5&#x02032;-UTR) and their A region, which is either encoded by different exons or deleted. The most abundant isoforms of RAR&#x003b1; in mice, RAR&#x003b1;1 and RAR&#x003b1;2, have also been cloned in human. The human RAR&#x003b1; gene, located on chromosome 17q21, consists of 10 exons (Fig. <xref ref-type="fig" rid="gke653f1">1</xref>A; adapted from refs <xref ref-type="bibr" rid="gke653c24">24</xref>&#x02013;<xref ref-type="bibr" rid="gke653c26">26</xref> and our unpublished observations). Two promoters, located in front of exons 1 and 3, control expression of RAR&#x003b1;1 and RAR&#x003b1;2. Start codons of RAR&#x003b1;1 and RAR&#x003b1;2 lie in exons 2 and 3, respectively. RAR&#x003b1;1 is expressed in a wide variety of tissues at similar levels (<xref ref-type="bibr" rid="gke653c27">27</xref>). In contrast, RAR&#x003b1;2 is expressed in a tissue-specific manner (<xref ref-type="bibr" rid="gke653c21">21</xref>) and is up-regulated upon RA- or granulocyte colony-stimulating factor-induced differentiation (<xref ref-type="bibr" rid="gke653c28">28</xref>,<xref ref-type="bibr" rid="gke653c29">29</xref>). The specific function of each isoform is unknown. Targeted disruptions of single RAR isotypes show normal embryonic development and adult phenotypes (reviewed in <xref ref-type="bibr" rid="gke653c30">30</xref>). However, compound null mutants for RAR&#x003b1;1 and total RAR&#x003b2;, for RAR&#x003b1;1 and total RAR&#x003b3; or for other RAR and&#x0002f;or RXR isoforms exhibit malformations and are short lived (<xref ref-type="bibr" rid="gke653c30">30</xref>). These data suggest that a degree of functional redundancy exists, but certain combinations of isoforms are irreplaceable, underlining the complexity of RA signaling.</p><p>In this paper, we report the identification of two new RAR&#x003b1; isoforms which result from usage of the A1 region and alternative splicing of other regions. One of these isoforms, designated RAR&#x003b1;1&#x00394;B, splices out the B region and, as a consequence of an altered reading frame and a premature termination codon, lacks the rest of the functional domains. The second isoform, designated RAR&#x003b1;1&#x00394;BC, splices out the B and C regions, which comprise the AF-1- and DNA-binding domains, while the remaining functional domains are intact. RAR&#x003b1;1&#x00394;BC represents an infrequent example of a functional nuclear receptor that deletes the DNA-binding domain.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Fresh cells and cell lines</title><p>Peripheral blood (PB) or bone marrow (BM) mononuclear cells (PBMC and BMMC, respectively) of normal donors and B chronic lymphocytic leukemia (B-CLL) patients were isolated by gradient centrifugation. PB CD3<sup>&#x0002b;</sup> T cells, CD19<sup>&#x0002b;</sup> B cells and CD56<sup>&#x0002b;</sup> natural killer (NK) cells from normal donors were separated using immunomagnetic particles and processed for RNA purification as previously described (<xref ref-type="bibr" rid="gke653c31">31</xref>). CD34<sup>&#x0002b;</sup> hematopoietic progenitor cells from the BM of normal individuals were purified using the Ceprate LC kit (CellPro, Bothell, WA). Myeloid cell lines NB4 (PML-RAR&#x003b1;-expressing acute promyelocytic leukemia), HL60 and U937, T cell acute leukemia cell line Jurkat, Epstein&#x02013;Barr virus (EBV)-negative Burkitt lymphoma (BL) cell line DG75 and an EBV-transformed B lymphoblastoid cell line derived from normal B cells (B-LCL) were cultured in RPMI-1640 medium, supplemented with 10&#x00025; fetal calf serum (FCS). Epithelial cell line MCF-7 and COS monkey fibroblasts were grown in DMEM with 10&#x00025; FCS.</p></sec><sec><title>Cloning and sequencing</title><p>A &#x003bb;DR2 cDNA expression library (Clontech, Palo Alto, CA) made from total RNA obtained from malignant cells of a B-CLL patient (1) was screened by hybridization as previously described (<xref ref-type="bibr" rid="gke653c32">32</xref>), using an RAR&#x003b1; probe (1.9 kb <italic>Eco</italic>RI fragment containing the entire coding region of human RAR&#x003b1;1 cDNA; <xref ref-type="bibr" rid="gke653c6">6</xref>). A positive clone was plaque purified, excised and circularized into the recombinant plasmid pDR2 as described by the manufacturer. The cloned insert was sequenced using an ABI automatic sequencer (Perkin Elmer, Branchburg, NJ), appearing to be a splice variant of RAR&#x003b1;1. The plasmid was called pDR2-RAR&#x003b1;1&#x00394;BC (see Results). RAR&#x003b1; cosmids 121 and 124 were gifts of E. Solomon (London, UK). Amplified RT&#x02013;PCR products (described below) from two B-CLL patients (1 and 2) and from a normal individual (CD19<sup>&#x0002b;</sup> 1) were cloned, using the pCR-Trap cloning vector primer kit (Genehunter, Nashville, TN), and sequenced. The DNAstar software was used for database searches and molecular biology programs (Madison, WI).</p></sec><sec><title>Semi-quantitative competitive RT&#x02013;PCR</title><p>Total RNA was obtained from human or mouse tissues or obtained from the fresh cells and cell lines described above. Part of the RNA panel of human tissues was purchased (Clontech). RNA (1, 0.3 or 0.1 &#x000b5;g) was reverse transcribed using random primers for 15 min at 42&#x000b0;C, followed by 25 cycles of PCR consisting of 25 s at 95&#x000b0;C, 1 min at 59&#x000b0;C and 3 min at 72&#x000b0;C, in a Perkin Elmer thermal cycler. The upstream primer R6 (5&#x02032;-GGTGCCTCCCTACGCCTTCT-3&#x02032;) was located within exon 2 of the RAR&#x003b1; gene. The downstream primer RARD&#x0002f;E (5&#x02032;-AGAGGGCAGGGAAGGTTTCC-3&#x02032;) was located within exon 6. PCR products were electrophoresed and blotted onto Hybond N<sup>&#x0002b;</sup> nylon membranes (Amersham, Little Chalfont, UK). Filters were hybridized with &#x0005b;&#x003b3;-<sup>32</sup>P&#x0005d;ATP-labeled oligonucleotide probes RAR21 (5&#x02032;-GAGCTCCCCCACCTCCGGCGT-3&#x02032;), upstream to RARD&#x0002f;E within exon 6, or RAR22 (5&#x02032;-TCCCCAGCCACTGTGAGAAAC-3&#x02032;), comprising the junction between exons 2 and 6, and autoradiographed. Mouse primers and probes were homologs of the human set: R6M (5&#x02032;-AGTACCCCCCTACGCCTTCT-3&#x02032;); RARD&#x0002f;EM (5&#x02032;-AGAGGGCCGGGAAGGTCTCC-3&#x02032;); RAR21M (5&#x02032;-GAGCTCGCCCACCTCAGGAGT-3&#x02032;); RAR22M (5&#x02032;-TCCCCAGCCACGGTGCGAAAC-3&#x02032;).</p></sec><sec><title>Constructions</title><p>For transient transfections, a pSG5-RAR&#x003b1;1&#x00394;BC construct was generated by excising a 2.2 kb <italic>Bam</italic>HI fragment from pDR2-RAR&#x003b1;1&#x00394;BC and subcloning into the <italic>Bam</italic>HI site of pSG5.The pSG5-hRAR&#x003b1;1 (<xref ref-type="bibr" rid="gke653c6">6</xref>) and pSG5-mRXR&#x003b1; (<xref ref-type="bibr" rid="gke653c4">4</xref>) expression vectors and the RARE<sub>3</sub>-tk-luc luciferase reporter (<xref ref-type="bibr" rid="gke653c33">33</xref>) were also used. The RSV-&#x003b2; plasmid (Promega, Madison, WI) was used as a control for transfection efficiency. To produce GST fusion recombinant protein, a pGEX-RAR&#x003b1;1&#x00394;BC construct was generated by PCR (20 cycles under the conditions described above), using pDR2-RAR&#x003b1;1&#x00394;BC as PCR template and primers carrying <italic>Eco</italic>RI and <italic>Xho</italic>I restriction sites at the 5&#x02032;-end (DBC-Eco, 5&#x02032;-TCTGAATTCATGGCCAGCAACAGCAGCTC-3&#x02032;; DBC-Xho, 5&#x02032;-AATCTCGAGTGTGTCCATGTGGCGTGGGC-3&#x02032;). The PCR product was digested with <italic>Eco</italic>RI and <italic>Xho</italic>I and cloned into the <italic>Eco</italic>RI and <italic>Xho</italic>I sites of pGEX-4T-1 (Pharmacia, Uppsala, Sweden). The pGEX-RAR&#x003b1;1 and pGEX-RXR&#x003b1; (<xref ref-type="bibr" rid="gke653c34">34</xref>) constructs were also used.</p></sec><sec><title>Antibodies</title><p>A rabbit polyclonal antibody directed against the F region of RAR&#x003b1; &#x0005b;RP&#x003b1;(F)&#x0005d; (<xref ref-type="bibr" rid="gke653c35">35</xref>) was used in western blot analysis. A rabbit antiserum directed against the predicted A1&#x02013;D domain junction of RAR&#x003b1;1&#x00394;BC was made by sequential intradermal injections using the synthetic peptide NH<sub>2</sub>-YSTPSPATVRNDRNKC-CONH<sub>2</sub> (Syntem, N&#x000ee;mes, France). This antibody, designated RP&#x003b1;1&#x00394;, was used in immunofluorescence studies. Mouse monoclonal antibodies (mAb) directed against the F region of RAR&#x003b1; &#x0005b;Ab9&#x003b1;(F)&#x0005d; (<xref ref-type="bibr" rid="gke653c35">35</xref>) and against the D&#x02013;E region of RXR&#x003b1; (4RX3A2) (<xref ref-type="bibr" rid="gke653c36">36</xref>) were also used in immunofluorescence as well as in electrophoretic mobility shift assay (EMSA) experiments.</p></sec><sec><title>Western blot analysis</title><p>The immunoblotting procedures have been previously described (<xref ref-type="bibr" rid="gke653c31">31</xref>,<xref ref-type="bibr" rid="gke653c37">37</xref>). Briefly, 10 &#x000b5;g whole cell protein extracts or 1 &#x000b5;g purified recombinant protein was fractionated on 10&#x00025; Tris&#x02013;glycine&#x0002f;SDS&#x0002f;polyacrylamide gels and electrotransferred onto Hybond-ECL nitrocellulose membranes (Amersham). Filters were blocked for 3 h in 5&#x00025; non-fat milk in PBS. After overnight incubation in PBS with RP&#x003b1;(F) diluted at 1:1000 or RP&#x003b1;1&#x00394; diluted at 1:100, the filters were washed five times for 10 min, blocked for 10 min in 2.5&#x00025; non-fat milk and incubated for 30 min with protein A linked to horseradish peroxidase (Amersham) diluted at 1:10 000. After five additional washes, the proteins were visualized using ECL chemiluminescent reagents.</p></sec><sec><title>Immunofluorescence</title><p>In order to localize RAR&#x003b1;1&#x00394;BC in the cell, immunofluorescence was undertaken on transiently transfected COS cells as previously described (<xref ref-type="bibr" rid="gke653c37">37</xref>). Briefly, cells were fixed in 4&#x00025; formaldehyde and incubated overnight at 4&#x000b0;C with RP&#x003b1;1&#x00394; or Ab9&#x003b1; antibodies at 1:100 dilution. Cells were visualized using fluorescein isothiocyanate (FITC)-conjugated anti-rabbit antibody at 1:100 dilution or cyanin 5 (cy5)-conjugated anti-mouse antibody at 1:50 dilution (Caltag, San Francisco, CA). Nuclei were stained with Hoechst 33258. Cells were analyzed by confocal fluorescence microscopy. As negative controls, non-transfected cells were stained in parallel using the antibodies.</p></sec><sec><title>Electrophoretic mobility shift assays</title><p>The procedures were similar to those previously described (<xref ref-type="bibr" rid="gke653c37">37</xref>). RAR&#x003b1;1, RXR&#x003b1; and RAR&#x003b1;1&#x00394;BC recombinant proteins were produced and purified from bacterial lysates and incubated, alone or in combinations, with double-stranded &#x0005b;&#x003b3;-<sup>32</sup>P&#x0005d;ATP-labeled probes made using the following oligonucleotides and their complements: DR5 RARE (5&#x02032;-GATCAGGGTTCACCGAAAGTTCACTCGCATATATTA-G-3&#x02032;) and DR1 RXRE (5&#x02032;-GATCAGGTCACAGGTCACAGGTCACAGTTCA-3&#x02032;). For supershifts, 1 &#x000b5;g Ab9&#x003b1;(F) or 4RX3A2 mAb was added 10 min before the recombinant protein. Binding reactions were electrophoresed in 10&#x00025; polyacrylamide gels for 1 h. Gels were dried and autoradiographed.</p></sec><sec><title><italic>In vitro</italic> interaction assay</title><p>GST &#x02018;pull-down&#x02019; assays were performed as previously described (<xref ref-type="bibr" rid="gke653c37">37</xref>). Briefly, bacterial lysates containing GST&#x02013;RXR&#x003b1; or GST protein were bound for 2 h on glutathione&#x02013;Sepharose beads. After four washes, beads were incubated for 1 h at 4&#x000b0;C with whole cell protein extracts of COS cells transfected with pSG5-RAR&#x003b1;1&#x00394;BC or pSG5-RAR&#x003b1;. After four washes, SDS loading buffer was added. Proteins were denatured for 10 min at 100&#x000b0;C, loaded onto SDS&#x02013;PAGE gels and processed for immunoblotting using the RP&#x003b1;(F) antibody as described above.</p></sec><sec><title>Transfections and transactivation assays</title><p>COS cells were transfected by the calcium phosphate precipitation method and B-LCL cells by electroporation, as described previously (<xref ref-type="bibr" rid="gke653c31">31</xref>). Briefly, 3 &#x000d7; 10<sup>5</sup> COS cells&#x0002f;35 mm dish were plated the day before transfection, then transfected with 0.1 &#x000b5;g each receptor plasmid following different combinations and 1 &#x000b5;g reporter constructs. B-LCL cells (20 &#x000d7; 10<sup>6</sup>) were electroporated in the presence of 5 &#x000b5;g each expression construct, 7.5 &#x000b5;g RARE<sub>3</sub>-tk-luc and 2.5 &#x000b5;g RSV-&#x003b2;. The quantities of DNA in each experiment were equalized with the pSG5 vector. Cells were grown in carbon-treated FCS (Gemini, Calabasas, CA) in the presence or absence of 10<sup>&#x02013;6</sup> M ATRA (Hoffman-La-Roche, Basel, Switzerland) or synthetic RAR agonist CD336 or RXR agonist CD2809 (CIRD-Galderma, Sophia Antipolis, France). A reporter lysis buffer was added to cells 24 h after transfection and protein was extracted according to the manufacturer&#x02019;s instructions (Promega). Standard assays were performed to measure luciferase (Promega) and &#x003b2;-galactosidase activities (Boehringer-Mannheim, Mannheim, Germany) using a Berthold luminometer. Luciferase activity was normalized to &#x003b2;-galactosidase activity. Each experiment was done in triplicate at least twice. Results are expressed as fold induction of luciferase activity induced by transfected receptors relative to the pSG5 vector.</p></sec></sec><sec><title>RESULTS</title><sec><title>Isolation of novel RAR&#x003b1; splice variants</title><p>Exons 1 and 2 of the RAR&#x003b1; gene encode the 5&#x02032;-UTR and A1 region of the RAR&#x003b1;1 isoform, exon 3 encodes the 5&#x02032;-UTR and A2 region of the RAR&#x003b1;2 isoform and exons 4 and 5 encompass regions B, C and the first 3 amino acids of D. The B&#x02013;F regions are common to both isoforms (Fig. <xref ref-type="fig" rid="gke653f1">1</xref>A and C; <xref ref-type="bibr" rid="gke653c21">21</xref>,<xref ref-type="bibr" rid="gke653c26">26</xref>). Screening a &#x003bb;DR2 cDNA library from a B-CLL patient (1) with a full-length RAR&#x003b1;1 cDNA probe revealed a clone which, upon sequencing, lacked exons 3&#x02013;5 of the RAR&#x003b1; gene. As the A1 region is retained in this clone and the major deleted regions are B and C, this variant receptor was designated RAR&#x003b1;1&#x00394;BC. The junction between exons 2 and 6 maintains the reading frame of the D region (Fig. <xref ref-type="fig" rid="gke653f1">1</xref>B). As a consequence, RAR&#x003b1;1&#x00394;BC represents a short form of the RAR&#x003b1;1 isoform where the A1 region is juxtaposed to the D&#x02013;E&#x02013;F regions (Fig. <xref ref-type="fig" rid="gke653f1">1</xref>C and D). Using primers flanking the A1&#x02013;D junction (R6 and RARD&#x0002f;E, Fig. <xref ref-type="fig" rid="gke653f1">1</xref>C), an RT&#x02013;PCR technique was set up to detect RAR&#x003b1;1&#x00394;BC in total RNA samples. By the use of such primers the RAR&#x003b1;1 isoform was co-amplified in the same tube. Southern blot analysis and hybridization with the RAR21 oligonucleotide probe, which comprises sequences of exon 6 upstream of RARD&#x0002f;E (Fig. <xref ref-type="fig" rid="gke653f1">1</xref>C), allowed specific and simultaneous detection of both RAR&#x003b1;1 and RAR&#x003b1;1&#x00394;BC amplified fragments (Fig. <xref ref-type="fig" rid="gke653f2">2</xref>A, left). Hybridization with the RAR22 oligonucleotide probe, which comprises the A1&#x02013;D junction (Fig. <xref ref-type="fig" rid="gke653f1">1</xref>C), allowed specific detection of the RAR&#x003b1;1&#x00394;BC fragment (Fig. <xref ref-type="fig" rid="gke653f2">2</xref>A, right). The RAR&#x003b1;1&#x00394;BC fragment was subsequently cloned from three independent RT&#x02013;PCR products, including one from the original patient (1), one from another B-CLL patient (2) and one from a normal individual (CD19<sup>&#x0002b;</sup> 1). Sequencing of these clones confirmed the A1&#x02013;D junction observed in the original RAR&#x003b1;1&#x00394;BC cDNA clone. The splice donor and acceptor sites were sequenced using RAR&#x003b1; cosmids and primers R6 and RARD&#x0002f;E (data not shown). Sequences previously reported of the exon 2&#x0002f;intron 2 and intron 5&#x0002f;exon 6 boundaries were confirmed (<xref ref-type="bibr" rid="gke653c24">24</xref>,<xref ref-type="bibr" rid="gke653c26">26</xref>).</p><p>The RT&#x02013;PCR method generated, in addition to the fragments corresponding to the RAR&#x003b1;1 and RAR&#x003b1;1&#x00394;BC mRNAs, another product of intermediate size detected with the RAR21 probe (Fig. <xref ref-type="fig" rid="gke653f2">2</xref>A, left). Cloning and sequencing of this product from the B-CLL patient 1 and normal CD19<sup>&#x0002b;</sup> 1 samples showed that it consisted of sequences of exon 2 juxtaposed to exon 5. Therefore, exon 4, which encodes the B and part of the C regions of RAR&#x003b1;, was deleted. Thus, this fragment may represent a novel RAR&#x003b1; isoform, which was designated RAR&#x003b1;1&#x00394;B (Fig. <xref ref-type="fig" rid="gke653f1">1</xref>C). The junction between exons 2 and 5 resulted in an altered reading frame and a stop codon in the C region at position 100 (Fig. <xref ref-type="fig" rid="gke653f1">1</xref>D). Therefore, RAR&#x003b1;1&#x00394;B represents a truncated form of RAR&#x003b1;1 where the A region is fused to a short amino acid stretch derived from exon 5 (C region) and which does not code for a functional receptor. In conclusion, we have isolated two new RAR&#x003b1; isoforms, RAR&#x003b1;1&#x00394;BC and RAR&#x003b1;1&#x00394;B, with the exceptional feature that other functional domains apart from the A region are spliced out.</p></sec><sec><title>Transcript and protein tissue expression and nuclear localization of RAR&#x003b1;1&#x00394;BC</title><p>The competitive RT&#x02013;PCR technique described above was used to detect expression of RAR&#x003b1;1&#x00394;BC and RAR&#x003b1;1&#x00394;B mRNAs in different tissues and cell lines. As the RAR&#x003b1;1 mRNA is expressed at similar levels in a broad spectrum of tissues, including hematopoietic cells (<xref ref-type="bibr" rid="gke653c27">27</xref>), it provides a competitor template which is appropriate as an RT&#x02013;PCR internal control. The RT&#x02013;PCR conditions were set up to end the reaction in the exponential phase of amplification of RAR&#x003b1;1, RAR&#x003b1;1&#x00394;B and RAR&#x003b1;1&#x00394;BC (data not shown). Therefore, Southern blot hybridization of the RT&#x02013;PCRs with the RAR21 probe provided a semi-quantitative analysis of the expression of the novel isoforms. From a panel of human tissues, RAR&#x003b1;1&#x00394;BC mRNA was expressed in mononuclear cells from bone marrow (Fig. <xref ref-type="fig" rid="gke653f2">2</xref>B, lane 1) and from peripheral blood (not shown). As previously shown (Fig. <xref ref-type="fig" rid="gke653f2">2</xref>A), RAR&#x003b1;1&#x00394;BC mRNA was also expressed in normal CD19<sup>&#x0002b;</sup> B lymphocytes and malignant B-CLL cells. In addition, it was expressed in CD3<sup>&#x0002b;</sup> T lymphocytes and CD56<sup>&#x0002b;</sup> NK cells (not shown). RAR&#x003b1;1&#x00394;BC mRNA was also detected as a less intense band in spleen, colon, small intestine, testis, trachea and lung (Fig. <xref ref-type="fig" rid="gke653f2">2</xref>B, lanes 2, 4, 5 and 7&#x02013;9, respectively). Lower levels or absence of RAR&#x003b1;1&#x00394;BC mRNA expression was observed in tissues such as thymus, prostate, liver, kidney, heart, brain, skin, breast, tonsil and thyroid (Fig. <xref ref-type="fig" rid="gke653f2">2</xref>B, lanes 3, 6 and 10&#x02013;17, respectively). RAR&#x003b1;1&#x00394;BC mRNA was not detected in a panel of mouse tissues which included brain, heart, kidney, liver, lung, skeletal muscles, spleen, lymph node and bone marrow in the presence of a positive signal for RAR&#x003b1;1 (data not shown).</p><p>Western blot analysis of transiently transfected COS cells with a polyclonal antibody against the F region of RAR&#x003b1; &#x0005b;RP&#x003b1;(F)&#x0005d; showed that, as expected from the nucleotide sequence of its cDNA, RAR&#x003b1;1&#x00394;BC is expressed as a 40 kDa protein (Fig. <xref ref-type="fig" rid="gke653f3">3</xref>A, lane 2), smaller than wild-type RAR&#x003b1;1 (50 kDa) (Fig. <xref ref-type="fig" rid="gke653f3">3</xref>A, lane 1). Native RAR&#x003b1;1&#x00394;BC protein of the same size was detected in nuclear extracts of HL60 and NB4 myeloid cell lines and total extracts of BMMC (Fig. <xref ref-type="fig" rid="gke653f3">3</xref>A, lanes 4, 6 and 8, respectively). However, it was not detected in total extracts of BM CD34<sup>&#x0002b;</sup> hematopoietic progenitor cells (lane 7), PBMC (not shown) or in nuclear extracts of monocytic U937, B lymphoid DG75, T lymphoid Jurkat or epithelial MCF-7 cell lines (not shown), in the presence of the signal for the RAR&#x003b1;1 isoform, which served as a control. Thus, from the panel of tissues and cell lines analyzed it can be concluded that RAR&#x003b1;1&#x00394;BC has a more restricted and weaker expression than RAR&#x003b1;1. Furthermore, as it is not expressed in mouse, RAR&#x003b1;1&#x00394;BC may be a human-specific RAR&#x003b1; isoform.</p><p>The presence of RAR&#x003b1;1&#x00394;BC in nuclear extracts is consistent with retention of the nuclear localization signal (NLS) of the RAR&#x003b1; main isoforms, located in the D region (<xref ref-type="bibr" rid="gke653c38">38</xref>). Nevertheless, experiments were performed to determine whether absence of the C domain, which is involved in DNA binding, affected subcellular localization of the receptor. A polyclonal antibody generated against the A1&#x02013;D junction (RP&#x003b1;1&#x00394;), which recognized RAR&#x003b1;1&#x00394;BC efficiently but RAR&#x003b1;1 only marginally, as shown by immunoblotting using recombinant proteins (Fig. <xref ref-type="fig" rid="gke653f3">3</xref>B, lane 6), was used. Immunofluorescence analysis of RAR&#x003b1;1&#x00394;BC-transfected COS cells labeled with the RP&#x003b1;1&#x00394; antibody showed that the RAR&#x003b1;1&#x00394;BC protein was located in the nucleus (Fig. <xref ref-type="fig" rid="gke653f3">3</xref>D), with a diffuse pattern similar to that of RAR&#x003b1;1, as shown in RAR&#x003b1;1-transfected COS cells labeled with a mAb against the F region &#x0005b;Ab9&#x003b1;(F)&#x0005d; (Fig. <xref ref-type="fig" rid="gke653f3">3</xref>C). Staining of non-transfected control cells using the antibodies did not produce significant background (data not shown). Thus, absence of the DNA-binding domain did not affect the subcellular distribution of RAR&#x003b1;1&#x00394;BC.</p></sec><sec><title>RAR&#x003b1;1&#x00394;BC is found in a complex which binds the RARE and RXRE, through interaction with RXR&#x003b1;</title><p>In RAR&#x003b1;, the B region contains the AF-1 activity and the C region contains the DNA-binding domain. To determine whether absence of the B and C regions might affect the DNA-binding capacity of RAR&#x003b1;1&#x00394;BC, EMSA analysis was performed using a DR5 RARE and the recombinant receptors. It was first observed that, on its own, RAR&#x003b1;1&#x00394;BC did not bind to a DR5 response element, unlike RAR&#x003b1;1 or RXR&#x003b1; (Fig. <xref ref-type="fig" rid="gke653f4">4</xref>A, compare lane 2 to lanes 3 and 4). However, when RAR&#x003b1;1&#x00394;BC was tested in the presence of RXR&#x003b1;, a retarded complex was observed (compare lanes 4 and 5). This complex was shifted with antibodies against either RAR&#x003b1; (lane 6) or RXR&#x003b1; (lane 7). The intensity of the complexes was less than that observed with the complex between RAR&#x003b1;1 and RXR&#x003b1; (lanes 8&#x02013;10), suggesting that RXR&#x003b1;&#x0002f;RAR&#x003b1;1 dimers bind the RARE more efficiently than RXR&#x003b1;&#x0002f;RAR&#x003b1;1&#x00394;BC dimers. Similar results were obtained with a DR1 RXRE (data not shown). Altogether, these results indicate that, though unable to bind DNA due to absence of the C region, RAR&#x003b1;1&#x00394;BC protein is still found in the complex which binds the RARE, probably through heterodimerization with RXR&#x003b1;.</p><p>To obtain additional evidence that RAR&#x003b1;1&#x00394;BC may interact with RXR&#x003b1;, GST &#x02018;pull down&#x02019; experiments were performed using a GST&#x02013;RXR&#x003b1; fusion protein bound to glutathione&#x02013;Sepharose beads. After immunoblotting, RAR&#x003b1;1&#x00394;BC was found to directly interact with RXR&#x003b1; in the absence of RA (Fig. <xref ref-type="fig" rid="gke653f4">4</xref>B, lane 6), as was RAR&#x003b1;1 (Fig. <xref ref-type="fig" rid="gke653f4">4</xref>B, lane 3).</p></sec><sec><title>RAR&#x003b1;1&#x00394;BC and RXR&#x003b1; contribute to the transactivation mediated by the RAR&#x003b1;1&#x00394;BC&#x0002f;RXR&#x003b1; heterodimer on DR5 response elements</title><p>The ability of RAR&#x003b1;1&#x00394;BC to bind RXR&#x003b1; raises the question of a potential dominant negative function of RAR&#x003b1;1&#x00394;BC on RAR&#x003b1;1. To test this hypothesis, the transactivation capacities of RAR&#x003b1;1&#x00394;BC were analyzed by luciferase reporter assays after transient co-transfection. Experiments performed in the presence of ATRA in COS cells (Fig. <xref ref-type="fig" rid="gke653f5">5</xref>, white bars) or in B-LCL cells (not shown) showed that, as expected, RAR&#x003b1;1&#x00394;BC alone could not significantly induce the activity of a luciferase reporter under the control of DR5 response elements (compare white bars 1 and 4), whereas expression of RAR&#x003b1; or RXR&#x003b1; induced 3- and 2.3-fold increases above empty vector (white bars 2 and 3, respectively). However, when co-expressed with RXR&#x003b1;, RAR&#x003b1;1&#x00394;BC significantly increased transactivation of the promoter, as did RAR&#x003b1;1, though to a lesser extent (3.2- and 4.6-fold, white bars 7 and 5, respectively), showing that <italic>in vitro</italic> RAR&#x003b1;1&#x00394;BC is a functional receptor when heterodimerized with RXR&#x003b1; and does not exert a dominant negative effect. These conclusions were further supported when RAR&#x003b1;1, RXR&#x003b1; and RAR&#x003b1;1&#x00394;BC were co-transfected (4.7-fold, white bar 8).</p><p>As ATRA isomerizes <italic>in vivo</italic> into 9-<italic>cis</italic>-RA, the ligand of RXR, specific retinoids were used to dissect the contribution of the receptors to the transactivating capacity of the RXR&#x003b1;&#x0002f;RAR&#x003b1;1&#x00394;BC heterodimers. As shown in Figure <xref ref-type="fig" rid="gke653f5">5</xref> (red bars), transactivation of the DR5 RARE induced by the RAR agonist CD336 through the RXR&#x003b1;&#x0002f;RAR&#x003b1;1&#x00394;BC heterodimer was dependent on binding of the ligand to RAR&#x003b1;1&#x00394;BC &#x0005b;compare red bars 7 and 3, representing 2.1- and 1.2-fold increases over empty vector (red bar 1), respectively&#x0005d;. When the RXR agonist CD2809 was used (Fig. <xref ref-type="fig" rid="gke653f5">5</xref>, green bars), transactivation mediated through RXR&#x003b1; (green bar 3) was inhibited by RAR&#x003b1;1 fixation (green bar 5). Interestingly, CD2809 induced transactivation through the RXR&#x003b1;&#x0002f;RAR&#x003b1;1&#x00394;BC heterodimer (green bar 7). These findings suggest that transactivation of the DR5 RARE by the RXR&#x003b1;&#x0002f;RAR&#x003b1;1 heterodimer is mediated only by RAR ligands, whilst both RAR and RXR ligands transactivate the DR5 RARE through binding to the RXR&#x003b1;&#x0002f;RAR&#x003b1;1&#x00394;BC heterodimer.</p></sec></sec><sec><title>DISCUSSION</title><p>A novel isoform of the RAR&#x003b1; gene derived from usage of promoter P1 and alternative splicing of the B and C regions was identified. This isoform, designated RAR&#x003b1;1&#x00394;BC, lacks the DNA-binding domain and part of the AF-1 domain, whereas the ligand-binding domain, AF-2 domain and other functional domains remain intact. A second isoform was detected, derived from usage of promoter P1 and alternative splicing of the B region. This isoform, designated RAR&#x003b1;1&#x00394;B, generates a premature termination codon and lacks most of the RAR functional domains, making it unlikely that it codes for a functional receptor. In addition, its mRNA expression appears to be minor, and we have not studied its significance further. In contrast, the RAR&#x003b1;1&#x00394;BC protein is expressed in hematopoietic cells, particularly in primary myeloid cells and cell lines. Whilst it was originally cloned from B-CLL cells, RAR&#x003b1;1&#x00394;BC mRNA was expressed at apparently equal levels in normal B lymphocytes and B-CLL cells, as observed by a sensitive RT&#x02013;PCR assay, ruling out the hypothesis of an association of RAR&#x003b1;1&#x00394;BC expression with malignant B lymphocytes.</p><p>The different spatial and temporal expression of the RAR&#x003b1;, &#x003b2; and &#x003b3; isoforms suggests that they have specific activities. RAR&#x003b1;1&#x00394;BC tissue expression was found to be more restricted and weaker than that of RAR&#x003b1;1, but with significant expression in myeloid cells. This suggests that this variant receptor may have distinct functions from RAR&#x003b1;1. Both receptors were localized in the nucleus, as expected from retention of the nuclear translocation signal in the D domain (<xref ref-type="bibr" rid="gke653c38">38</xref>), and were found in the same nuclear compartment. As for the rest of the RAR isoforms, the exact role of RAR&#x003b1;1&#x00394;BC remains to be elucidated. The RARs are phosphoproteins and phosphorylation of specific serine residues influence their functional properties. Two Ser-Pro motifs within the B region of RAR&#x003b1;, S74 and S77, which are targets for CDK7 within TFIIH, are critical for AF-1 activity and transcription of RA-inducible genes (<xref ref-type="bibr" rid="gke653c39">39</xref>&#x02013;<xref ref-type="bibr" rid="gke653c41">41</xref>). Another serine of RAR&#x003b1;1, S157, can be phosphorylated <italic>in vitro</italic> by protein kinase C (<xref ref-type="bibr" rid="gke653c42">42</xref>). Although the exact role of these post-translational modifications has not yet been defined, the absence of these residues in RAR&#x003b1;1&#x00394;BC further suggests a divergent role from RAR&#x003b1;1.</p><p>The transcriptional properties of RAR&#x003b1;1&#x00394;BC and RAR&#x003b1;1 were compared. Absence of the DNA-binding domain would explain why RAR&#x003b1;1&#x00394;BC bound to neither a DR5 RARE nor to a DR1 RXRE. Nevertheless, our results show that it can interact with RXR&#x003b1; in the absence of ligand, consistent with presence of the heterodimerization interface. Moreover, these heterodimers bind to RARE and RXRE, likely through the RXR&#x003b1; half-site, although apparently with less affinity than RXR&#x003b1;&#x0002f;RAR&#x003b1;1 heterodimers. Despite this, the RXR&#x003b1;&#x0002f;RAR&#x003b1;1&#x00394;BC heterodimers are functional in transactivating a DR5 RARE in transfected COS cells in the presence of ATRA or an RAR-specific retinoid. Thus, our results rule out that RAR&#x003b1;1&#x00394;BC could exert a dominant negative effect and suggest that binding of the RXR&#x003b1;&#x0002f;RAR&#x003b1;1&#x00394;BC heterodimer through the RXR half-site of the RARE would be sufficient to transduce the activating signal triggered by RA. Furthermore, the results of our transactivation experiments using RAR- and RXR-specific retinoids allow us to conclude that whereas transactivation through RXR&#x003b1;&#x0002f;RAR&#x003b1;1 is mediated preferentially or exclusively by RAR ligands (reviewed in <xref ref-type="bibr" rid="gke653c17">17</xref>), transactivation through RXR&#x003b1;&#x0002f;RAR&#x003b1;1&#x00394;BC may be mediated by both RAR and RXR ligands. An interesting question which remains to be elucidated is whether the response element repertoire of the RXR&#x003b1;&#x0002f;RAR&#x003b1;1&#x00394;BC heterodimer differs from that of the regular RXR&#x003b1;&#x0002f;RAR&#x003b1; heterodimer in a target gene promoter context. Although further studies are needed to investigate their specific function, RAR&#x003b1;1&#x00394;B and RAR&#x003b1;1&#x00394;BC represent a new class of receptor variants which may provide another tier of control in RA signaling.</p></sec></body><back><sec sec-type="display-objects"><title>Figures and Tables</title><fig id="gke653f1"><label>Figure 1</label><caption><p> Isolation of novel RAR&#x003b1; isoforms. (<bold>A</bold>) Schematic representation of the genomic structure of the human RAR&#x003b1; gene (adapted from refs 24&#x02013;26 and our unpublished observations). Exons, numbered 1&#x02013;10, are represented as black boxes. Exons encoding the different domains, A&#x02013;F, are indicated. Two promoters, P1 and P2, located in front of exons 1 and 3, give rise to the alternative domains A1 and A2, present in the isoforms RAR&#x003b1;1 and RAR&#x003b1;2 &#x0005b;detailed in (C)&#x0005d;. (<bold>B</bold>) Trace from the sequencing of the junction between exons 2 and 6 of the RAR&#x003b1;1&#x00394;BC isoform. The predicted amino acid sequence of the junction following the open reading frame is indicated. (<bold>C</bold>) Schematic representation of the human RAR&#x003b1; isoforms. The predicted sequence of RAR&#x003b1;1&#x00394;B has an altered reading frame from R60 until the stop codon at position 100, designated the C&#x02032; domain. Oligonucleotides used as RT&#x02013;PCR primers, R6 and RARD&#x0002f;E, or as Southern blotting probes, RAR21 and RAR22, are drawn at their approximated positions. (<bold>D</bold>) Predicted amino acid sequence of novel isoforms RAR&#x003b1;1&#x00394;BC and RAR&#x003b1;1&#x00394;B. Amino acids of the junction &#x0005b;detailed in (B)&#x0005d; are underlined.</p></caption><graphic xlink:href="gke65301"/></fig><fig id="gke653f2"><label>Figure 2</label><caption><p> RAR&#x003b1;1&#x00394;BC mRNA is expressed at the highest levels in fresh hematopoietic cells. (<bold>A</bold>) Southern blot of semi-quantitative competitive RT&#x02013;PCR products using different quantities of total RNA (1&#x02013;0.1 &#x000b5;g, indicated at the top of the blots) from one B-CLL patient (no. 1) and one normal purified CD19<sup>&#x0002b;</sup> B cell sample (no. 1) using primers R6 and RARD&#x0002f;E. Specific bands corresponding to RAR&#x003b1;1, RAR&#x003b1;1&#x00394;B and RAR&#x003b1;1&#x00394;BC were detected using the RAR21 probe (left). The same blot was reprobed with RAR22 to the A1&#x02013;D junction (right), which is specific for the RAR&#x003b1;1&#x00394;BC isoform. The size of the PCR products is indicated on the right. (<bold>B</bold>) As (A) with 1 &#x000b5;g RNA from different human tissues using the RAR21 probe.</p></caption><graphic xlink:href="gke65302"/></fig><fig id="gke653f3"><label>Figure 3</label><caption><p> The RAR&#x003b1;1&#x00394;BC protein is expressed in hematopoietic myeloid cells and is nuclear. (<bold>A</bold>) Western blot analysis using 10 &#x000b5;g whole cell extracts from COS cells transfected with pSG5-RAR&#x003b1;1 (lane 1) or pSG5-RAR&#x003b1;1&#x00394;BC (lane 2), BM purified CD34<sup>&#x0002b;</sup> cells (lane 7), BMMC (lane 8) and cytoplasmic and nuclear extracts from HL60 (lanes 3 and 4, respectively) and NB4 (lanes 5 and 6, respectively) cells, using the RAR&#x003b1; antibody RP&#x003b1;(F). (<bold>B</bold>) Western blot analysis of purified recombinant proteins (RAR&#x003b1;1, RXR&#x003b1; and RAR&#x003b1;1&#x00394;BC) with RAR&#x003b1;(F) (lanes 1&#x02013;3) or RP&#x003b1;1&#x00394; made against the A1&#x02013;D junction (lanes 4&#x02013;6), showing that this antibody is specific for the RAR&#x003b1;1&#x00394;BC isoform. (<bold>C</bold>) Immunofluorescence analysis of COS cells transfected with RAR&#x003b1;1, labeled with a mAb against RAR&#x003b1; (Ab9&#x003b1;) and visualized with cyanin 5 (cy5)-conjugated anti-mouse antibody. (<bold>D</bold>) As (C) except that COS cells were transfected with RAR&#x003b1;1&#x00394;BC, labeled with RP&#x003b1;1&#x00394; and visualized with a FITC-conjugated anti-rabbit antibody, showing that RAR&#x003b1;1&#x00394;BC, like RAR&#x003b1;1, is located in the nucleus.</p></caption><graphic xlink:href="gke65303"/></fig><fig id="gke653f4"><label>Figure 4</label><caption><p> RAR&#x003b1;1&#x00394;BC alone does not bind a DR5 response element, but can bind RXR&#x003b1; and be found in the complex that binds DR5. (<bold>A</bold>) EMSA using purified recombinant proteins (RAR&#x003b1;1, RXR&#x003b1; and RAR&#x003b1;1&#x00394;BC) shows that RAR&#x003b1;1&#x00394;BC does not bind the RARE DR5 (lane 2), unlike RAR&#x003b1;1 and RXR&#x003b1; (lanes 3 and 4, respectively). When RAR&#x003b1;1&#x00394;BC and RXR&#x003b1; are incubated together (lane 5), a retarded complex is observed; this complex was shifted with a RAR&#x003b1; mAb (Ab9&#x003b1;, lane 6) and a RXR&#x003b1; mAb (4RX3A2, lane 7). A complex is also observed when RAR&#x003b1;1 and RXR&#x003b1; are co-incubated (lane 8), which shifted with the same antibodies (lanes 9 and 10). (<bold>B</bold>) GST &#x02018;pull down&#x02019; experiments using immobilized GST&#x02013;RXR&#x003b1; or GST proteins and whole cell extracts from COS cells transfected with RAR&#x003b1;1 (lanes 1&#x02013;3) or RAR&#x003b1;1&#x00394;BC (lanes 4&#x02013;6). Like RAR&#x003b1;1, RAR&#x003b1;1&#x00394;BC directly interacts with RXR&#x003b1; <italic>in vitro</italic>.</p></caption><graphic xlink:href="gke65304"/></fig><fig id="gke653f5"><label>Figure 5</label><caption><p> Transactivation of a RARE through combinations of the RXR&#x003b1;, RAR&#x003b1;1 and RAR&#x003b1;1&#x00394;BC receptors upon binding to the retinoids ATRA (white bars), RAR agonist CD336 (red bars) or RXR agonist CD2809 (green bars). RAR&#x003b1;1&#x00394;BC alone does not produce significant activity of the RARE<sub>3</sub>-tk-luc reporter in COS cells (lane 4); the RXR&#x003b1;&#x0002f;RAR&#x003b1;1&#x00394;BC heterodimers transactivate a RARE upon binding to ATRA, CD336 or CD2809 (lane 7); RXR&#x003b1;&#x0002f;RAR&#x003b1;1 transduces the transactivating signal mediated by ATRA and CD336 (lane 5); RAR&#x003b1;1 fixation inhibits the transactivation mediated by CD2809 binding to RXR&#x003b1; (lanes 5 and 3, green bars, respectively). Luciferase activities were normalized to &#x003b2;-galactosidase activities. A representative experiment, done in triplicate, is shown. All the retinoids were used at 10<sup>&#x02013;6</sup> M. The results are expressed as fold induction produced by the transfected receptors related to pSG5 empty vector in the presence of ATRA.</p></caption><graphic xlink:href="gke65305"/></fig></sec><ack><sec><title>ACKNOWLEDGEMENTS</title><p>We thank P. Chambon for the RAR&#x003b1;1 and RXR&#x003b1; plasmids and antibodies, H. de Th&#x000e9; for the RAR&#x003b1;, PML-RAR&#x003b1; and RARE<sub>3</sub>-tk-luc plasmids and useful discussions, E. Solomon for the RAR&#x003b1; cosmids and Fabien Zassadowski, Nicole Balitrand, Michel Schmid and Christelle Dolliger for technical assistance. This work was supported by grants from the Leukaemia Research Fund of Great Britain, the Welsh Bone Marrow Transplant Research Fund, the Ligue Nationale Contre le Cancer of France, the Association pour la Recherche contre le Cancer and Subprograma para el Perfeccionamiento de Doctores y Tecn&#x000f3;logos del Ministerio de Educaci&#x000f3;n y Ciencia of Spain.</p></sec></ack><ref-list><title>REFERENCES</title><ref id="gke653c1"><label>1.</label><citation citation-type="journal"><name><surname>Wendling</surname><given-names>O.</given-names></name>, Ghyselinck,N.B., Chambon,P. and Mark,M. (2001) Roles of retinoic acid receptors in early embryonic morphogenesis and hindbrain patterning. <source>Development</source>, <volume>128</volume>, <fpage>2031</fpage>&#x02013;<lpage>2038</lpage>.<pub-id pub-id-type="pmid">11493525</pub-id></citation></ref><ref id="gke653c2"><label>2.</label><citation citation-type="journal"><name><surname>Mangelsdorf</surname><given-names>D.J.</given-names></name>, Thummel,C., Beato,M., Herrlich,P., Schutz,G., Umesono,K., Blumberg,B., Kastner,P., Mark,M., Chambon,P. and Evans,R.M. (1995) The nuclear receptor family: the second decade. <source>Cell</source>, <volume>83</volume>, <fpage>835</fpage>&#x02013;<lpage>839</lpage>.<pub-id pub-id-type="pmid">8521507</pub-id></citation></ref><ref id="gke653c3"><label>3.</label><citation citation-type="journal"><name><surname>Petkovich</surname><given-names>M.</given-names></name>, Brand,N.J., Krust,A. and Chambon,P. (1987) A human retinoic acid receptor which belongs to the family of nuclear receptors. <source>Nature</source>, <volume>330</volume>, <fpage>444</fpage>&#x02013;<lpage>450</lpage>.<pub-id pub-id-type="pmid">2825025</pub-id></citation></ref><ref id="gke653c4"><label>4.</label><citation citation-type="journal"><name><surname>Leid</surname><given-names>M.</given-names></name>, Kastner,P., Lyons,R., Nakshatri,H., Saunders,M., Zacharewski,T., Chen,J.Y., Staub,A., Garnier,J.M., Mader,S. and Chambon,P. (1992) Purification, cloning and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. <source>Cell</source>, <volume>68</volume>, <fpage>377</fpage>&#x02013;<lpage>395</lpage>.<pub-id pub-id-type="pmid">1310259</pub-id></citation></ref><ref id="gke653c5"><label>5.</label><citation citation-type="journal"><name><surname>Heyman</surname><given-names>R.A.</given-names></name>, Mangelsdorf,D.J., Dyck,J.A., Stein,R.B., Eichele,G., Evans,R.M. and Thaller,C. (1992) 9-cis Retinoic acid is a high affinity ligand for the retinoid X receptor. <source>Cell</source>, <volume>68</volume>, <fpage>397</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">1310260</pub-id></citation></ref><ref id="gke653c6"><label>6.</label><citation citation-type="journal"><name><surname>Brand</surname><given-names>N.</given-names></name>, Petkovich,M., Krust,A., Chambon,P., de The,H., Marchio,A., Tiollais,P. and Dejean,A. (1988) Identification of a second human retinoic acid receptor. <source>Nature</source>, <volume>332</volume>, <fpage>850</fpage>&#x02013;<lpage>853</lpage>.<pub-id pub-id-type="pmid">2833708</pub-id></citation></ref><ref id="gke653c7"><label>7.</label><citation citation-type="journal"><name><surname>Krust</surname><given-names>A.</given-names></name>, Kastner,P., Petkovich,M., Zelent,A. and Chambon,P. (1989) A third human retinoic acid receptor, hRAR-&#x003b3;. <source>Proc. Natl Acad. Sci. USA</source>, <volume>86</volume>, <fpage>5310</fpage>&#x02013;<lpage>5314</lpage>.<pub-id pub-id-type="pmid">2546152</pub-id></citation></ref><ref id="gke653c8"><label>8.</label><citation citation-type="journal"><name><surname>Mangelsdorf</surname><given-names>D.J.</given-names></name>, Borgmeyer,U., Heyman,R.A., Zhou,J.Y., Ong,E.S., Oro,A.E., Kakizuka,A. and Evans,R.M. (1992) Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. <source>Genes Dev.</source>, <volume>6</volume>, <fpage>329</fpage>&#x02013;<lpage>344</lpage>.<pub-id pub-id-type="pmid">1312497</pub-id></citation></ref><ref id="gke653c9"><label>9.</label><citation citation-type="journal"><name><surname>Nagpal</surname><given-names>S.</given-names></name>, Friant,S., Nakshatri,H. and Chambon,P. (1993) RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization <italic>in vivo</italic>. <source>EMBO J.</source>, <volume>12</volume>, <fpage>2349</fpage>&#x02013;<lpage>2360</lpage>.<pub-id pub-id-type="pmid">8389696</pub-id></citation></ref><ref id="gke653c10"><label>10.</label><citation citation-type="journal"> de <name><surname>The</surname><given-names>H.</given-names></name>, Vivanco-Ruiz,M.M., Tiollais,P., Stunnenberg,H. and Dejean,A. (1990) Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene. <source>Nature</source>, <volume>343</volume>, <fpage>177</fpage>&#x02013;<lpage>180</lpage>.<pub-id pub-id-type="pmid">2153268</pub-id></citation></ref><ref id="gke653c11"><label>11.</label><citation citation-type="journal"><name><surname>Leroy</surname><given-names>P.</given-names></name>, Nakshatri,H. and Chambon,P. (1991) Mouse retinoic acid receptor alpha 2 isoform is transcribed from a promoter that contains a retinoic acid response element. <source>Proc. Natl Acad. Sci. USA</source>, <volume>88</volume>, <fpage>10138</fpage>&#x02013;<lpage>10142</lpage>.<pub-id pub-id-type="pmid">1658797</pub-id></citation></ref><ref id="gke653c12"><label>12.</label><citation citation-type="journal"><name><surname>Umesono</surname><given-names>K.</given-names></name>, Murakami,K.K., Thompson,C.C. and Evans,R.M. (1991) Direct repeats as selective response elements for the thyroid hormone, retinoic acid and vitamin D3 receptors. <source>Cell</source>, <volume>65</volume>, <fpage>1255</fpage>&#x02013;<lpage>1266</lpage>.<pub-id pub-id-type="pmid">1648450</pub-id></citation></ref><ref id="gke653c13"><label>13.</label><citation citation-type="journal"><name><surname>Naar</surname><given-names>A.M.</given-names></name>, Boutin,J.M., Lipkin,S.M., Yu,V.C., Holloway,J.M., Glass,C.K. and Rosenfeld,M.G. (1991) The orientation and spacing of core DNA-binding motifs dictate selective transcriptional responses to three nuclear receptors. <source>Cell</source>, <volume>65</volume>, <fpage>1267</fpage>&#x02013;<lpage>1279</lpage>.<pub-id pub-id-type="pmid">1648451</pub-id></citation></ref><ref id="gke653c14"><label>14.</label><citation citation-type="journal"><name><surname>Nagpal</surname><given-names>S.</given-names></name>, Saunders,M., Kastner,P., Durand,B., Nakshatri,H. and Chambon,P. (1992) Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. <source>Cell</source>, <volume>70</volume>, <fpage>1007</fpage>&#x02013;<lpage>1019</lpage>.<pub-id pub-id-type="pmid">1326406</pub-id></citation></ref><ref id="gke653c15"><label>15.</label><citation citation-type="journal"><name><surname>Xu</surname><given-names>L.</given-names></name>, Glass,C.K. and Rosenfeld,M.G. (1999) Coactivator and corepressor complexes in nuclear receptor function. <source>Curr. Opin. Genet. Dev.</source>, <volume>9</volume>, <fpage>140</fpage>&#x02013;<lpage>147</lpage>.<pub-id pub-id-type="pmid">10322133</pub-id></citation></ref><ref id="gke653c16"><label>16.</label><citation citation-type="journal"><name><surname>Kastner</surname><given-names>P.</given-names></name>, Mark,M., Ghyselinck,N., Krezel,W., Dupe,V., Grondona,J.M. and Chambon,P. (1997) Genetic evidence that the retinoid signal is transduced by heterodimeric RXR&#x0002f;RAR functional units during mouse development. <source>Development</source>, <volume>124</volume>, <fpage>313</fpage>&#x02013;<lpage>326</lpage>.<pub-id pub-id-type="pmid">9053308</pub-id></citation></ref><ref id="gke653c17"><label>17.</label><citation citation-type="journal"><name><surname>Moras</surname><given-names>D.</given-names></name> and Gronemeyer,H. (1998) The nuclear receptor ligand-binding domain: structure and function. <source>Curr. Opin. Cell Biol.</source>, <volume>10</volume>, <fpage>384</fpage>&#x02013;<lpage>391</lpage>.<pub-id pub-id-type="pmid">9640540</pub-id></citation></ref><ref id="gke653c18"><label>18.</label><citation citation-type="journal"><name><surname>Jenuwein</surname><given-names>T.</given-names></name> and Allis,C.D. (2001) Translating the histone code. <source>Science</source>, <volume>293</volume>, <fpage>1074</fpage>&#x02013;<lpage>1080</lpage>.<pub-id pub-id-type="pmid">11498575</pub-id></citation></ref><ref id="gke653c19"><label>19.</label><citation citation-type="journal"><name><surname>Giguere</surname><given-names>V.</given-names></name>, Shago,M., Zirngibl,R., Tate,P., Rossant,J. and Varmuza,S. (1990) Identification of a novel isoform of the retinoic acid receptor gamma expressed in the mouse embryo. <source>Mol. Cell. Biol.</source>, <volume>10</volume>, <fpage>2335</fpage>&#x02013;<lpage>2340</lpage>.<pub-id pub-id-type="pmid">2157970</pub-id></citation></ref><ref id="gke653c20"><label>20.</label><citation citation-type="journal"><name><surname>Kastner</surname><given-names>P.</given-names></name>, Krust,A., Mendelsohn,C., Garnier,J.M., Zelent,A., Leroy,P., Staub,A. and Chambon,P. (1990) Murine isoforms of retinoic acid receptor gamma with specific patterns of expression. <source>Proc. Natl Acad. Sci. USA</source>, <volume>87</volume>, <fpage>2700</fpage>&#x02013;<lpage>2704</lpage>.<pub-id pub-id-type="pmid">2157210</pub-id></citation></ref><ref id="gke653c21"><label>21.</label><citation citation-type="journal"><name><surname>Leroy</surname><given-names>P.</given-names></name>, Krust,A., Zelent,A., Mendelsohn,C., Garnier,J.M., Kastner,P., Dierich,A. and Chambon,P. (1991) Multiple isoforms of the mouse retinoic acid receptor alpha are generated by alternative splicing and differential induction by retinoic acid. <source>EMBO J.</source>, <volume>10</volume>, <fpage>59</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">1846598</pub-id></citation></ref><ref id="gke653c22"><label>22.</label><citation citation-type="journal"><name><surname>Zelent</surname><given-names>A.</given-names></name>, Mendelsohn,C., Kastner,P., Krust,A., Garnier,J.M., Ruffenach,F., Leroy,P. and Chambon,P. (1991) Differentially expressed isoforms of the mouse retinoic acid receptor beta generated by usage of two promoters and alternative splicing. <source>EMBO J.</source>, <volume>10</volume>, <fpage>71</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">1846599</pub-id></citation></ref><ref id="gke653c23"><label>23.</label><citation citation-type="journal"><name><surname>Nagpal</surname><given-names>S.</given-names></name>, Zelent,A. and Chambon,P. (1992) RAR-beta 4, a retinoic acid receptor isoform is generated from RAR-beta 2 by alternative splicing and usage of a CUG initiator codon. <source>Proc. Natl Acad. Sci. USA</source>, <volume>89</volume>, <fpage>2718</fpage>&#x02013;<lpage>2722</lpage>.<pub-id pub-id-type="pmid">1313565</pub-id></citation></ref><ref id="gke653c24"><label>24.</label><citation citation-type="journal"><name><surname>Brand</surname><given-names>N.J.</given-names></name>, Petkovich,M. and Chambon,P. (1990) Characterization of a functional promoter for the human retinoic acid receptor-alpha (hRAR-alpha). <source>Nucleic Acids Res.</source>, <volume>18</volume>, <fpage>6799</fpage>&#x02013;<lpage>6806</lpage>.<pub-id pub-id-type="pmid">2175878</pub-id></citation></ref><ref id="gke653c25"><label>25.</label><citation citation-type="journal"><name><surname>Pandolfi</surname><given-names>P.P.</given-names></name>, Alcalay,M., Fagioli,M., Zangrilli,D., Mencarelli,A., Diverio,D., Biondi,A., Lo Coco,F., Rambaldi,A., Grignani,F., Rochette-Egly,C., Gaube,M.P., Chambon,P. and Pelicci,P.G. (1992) Genomic variability and alternative splicing generate multiple PML&#x0002f;RAR alpha transcripts that encode aberrant PML proteins and PML&#x0002f;RAR alpha isoforms in acute promyelocytic leukaemia. <source>EMBO J.</source>, <volume>11</volume>, <fpage>1397</fpage>&#x02013;<lpage>1407</lpage>.<pub-id pub-id-type="pmid">1314166</pub-id></citation></ref><ref id="gke653c26"><label>26.</label><citation citation-type="journal"><name><surname>Hjalt</surname><given-names>T.A.H.</given-names></name> and Murray,J.C. (1999) Genomic structure of the human retinoic acid receptor-alpha1 gene. <source>Mamm. Genome</source>, <volume>10</volume>, <fpage>528</fpage>&#x02013;<lpage>529</lpage>.<pub-id pub-id-type="pmid">10337631</pub-id></citation></ref><ref id="gke653c27"><label>27.</label><citation citation-type="journal"> de <name><surname>The</surname><given-names>H.</given-names></name>, Marchio,A., Tiollais,P. and Dejean,A. (1989) Differential expression and ligand regulation of the retinoic acid receptor alpha and beta genes. <source>EMBO J.</source>, <volume>8</volume>, <fpage>429</fpage>&#x02013;<lpage>433</lpage>.<pub-id pub-id-type="pmid">2542014</pub-id></citation></ref><ref id="gke653c28"><label>28.</label><citation citation-type="journal"><name><surname>Zelent</surname><given-names>A.</given-names></name>, Enver,T., Gallagher,R. and Waxman,S. (1996) RAR&#x003b1;2 isoform in normal granulopoiesis and leukemia. <source>Blood</source>, <volume>88</volume> (suppl. 1), <fpage>52</fpage> (abstract).</citation></ref><ref id="gke653c29"><label>29.</label><citation citation-type="journal"><name><surname>Zelent</surname><given-names>A.</given-names></name>, Zhu,J., Lanotte,M., Gallagher,R., Waxman,S., Heyworth,C.M. and Enver,T. (1997) Differential expression of retinoic receptors during multilineage differentiation of haemopoietic progenitor cells&#x02014;role of the RAR&#x003b1;2 isoform in normal granulopoiesis and leukaemia. <source>Blood</source>, <volume>90</volume> (suppl. 1), <fpage>44</fpage>&#x02013;<lpage>45</lpage> (abstract).</citation></ref><ref id="gke653c30"><label>30.</label><citation citation-type="journal"><name><surname>Mark</surname><given-names>M.</given-names></name>, Ghyselinck,N.B., Wendling,O., Dupe,V., Mascrez,B., Kastner,P. and Chambon,P. (1999) A genetic dissection of the retinoid signalling pathway in the mouse. <source>Proc. Nutr. Soc.</source>, <volume>58</volume>, <fpage>609</fpage>&#x02013;<lpage>613</lpage>.<pub-id pub-id-type="pmid">10604193</pub-id></citation></ref><ref id="gke653c31"><label>31.</label><citation citation-type="journal"><name><surname>Parrado</surname><given-names>A.</given-names></name>, Noguera,M.E., Delmer,A., McKenna,S., Davies,J., Le Gall,I., Bentley,P., Whittaker,J., Sigaux,F., Chomienne,C. and Padua,R.A. (2000) Deregulated expression of leukemia translocation protein PLZF in B-cell chronic lymphocytic leukemias (B-CLL) does not affect cyclin A expression. <source>Hematol. J.</source>, <volume>1</volume>, <fpage>15</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">11920165</pub-id></citation></ref><ref id="gke653c32"><label>32.</label><citation citation-type="other"><name><surname>Sambrook</surname><given-names>J.</given-names></name>, Fritsch,E.F. and Maniatis,T. (1989) <italic>Molecular Cloning: A Laboratory Manual</italic>, 2nd Edn. Cold Spring Harbor Laboratory Press, Plainview, NY.</citation></ref><ref id="gke653c33"><label>33.</label><citation citation-type="journal"> de <name><surname>The</surname><given-names>H.</given-names></name>, Lavau,C., Marchio,A., Chomienne,C., Degos,L. and Dejean,A. (1991) The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. <source>Cell</source>, <volume>66</volume>, <fpage>675</fpage>&#x02013;<lpage>684</lpage>.<pub-id pub-id-type="pmid">1652369</pub-id></citation></ref><ref id="gke653c34"><label>34.</label><citation citation-type="journal"> Le <name><surname>Douarin</surname><given-names>B.</given-names></name>, Zechel,C., Garnier,J.M., Lutz,Y., Tora,L., Pierrat,P., Heery,D., Gronemeyer,H., Chambon,P. and Losson,R. (1995) The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. <source>EMBO J.</source>, <volume>14</volume>, <fpage>2020</fpage>&#x02013;<lpage>2033</lpage>.<pub-id pub-id-type="pmid">7744009</pub-id></citation></ref><ref id="gke653c35"><label>35.</label><citation citation-type="journal"><name><surname>Gaub</surname><given-names>M.P.</given-names></name>, Rochette-Egly,C., Lutz,Y., Ali,S., Matthes,H., Scheuer,I. and Chambon,P. (1992) Immunodetection of multiple species of retinoic acid receptor alpha: evidence for phosphorylation. <source>Exp. Cell Res.</source>, <volume>201</volume>, <fpage>335</fpage>&#x02013;<lpage>346</lpage>.<pub-id pub-id-type="pmid">1322315</pub-id></citation></ref><ref id="gke653c36"><label>36.</label><citation citation-type="journal"><name><surname>Rochette-Egly</surname><given-names>C.</given-names></name>, Lutz,Y., Pfister,V., Heyberger,S., Scheuer,I., Chambon,P. and Gaub,M.P. (1994) Detection of retinoid X receptors using specific monoclonal and polyclonal antibodies. <source>Biochem. Biophys. Res. Commun.</source>, <volume>204</volume>, <fpage>525</fpage>&#x02013;<lpage>536</lpage>.<pub-id pub-id-type="pmid">7980510</pub-id></citation></ref><ref id="gke653c37"><label>37.</label><citation citation-type="journal"><name><surname>Delva</surname><given-names>L.</given-names></name>, Bastie,J.N., Rochette-Egly,C., Kra&#x000ef;ba,R., Balitrand,N., Despouy,G., Chambon,P. and Chomienne,C. (1999) Physical and functional interactions between cellular retinoic acid binding protein II and the retinoic acid-dependent nuclear complex. <source>Mol. Cell. Biol.</source>, <volume>19</volume>, <fpage>7158</fpage>&#x02013;<lpage>7167</lpage>.<pub-id pub-id-type="pmid">10490651</pub-id></citation></ref><ref id="gke653c38"><label>38.</label><citation citation-type="other"><name><surname>Chambon</surname><given-names>P.</given-names></name>, Zelent,A., Petkovich,M., Mendelsohn,C., Leroy,P., Krust,A., Kastner,P. and Brand,N. (1991) The family of retinoic acid nuclear receptors. In Saurat,J.H. (ed.), <italic>Retinoids: 10 Years On</italic>. Karger, Basel, Switzerland, pp. <fpage>10</fpage>&#x02013;<lpage>27</lpage>.</citation></ref><ref id="gke653c39"><label>39.</label><citation citation-type="journal"><name><surname>Rochette-Egly</surname><given-names>C.</given-names></name>, Oulad-Abdelghani,M., Staub,A., Pfister,V., Scheuer,I., Chambon,P. and Gaub,M.P. (1995) Phosphorylation of the retinoic acid receptor-alpha by protein kinase A. <source>Mol. Endocrinol.</source>, <volume>9</volume>, <fpage>860</fpage>&#x02013;<lpage>871</lpage>.<pub-id pub-id-type="pmid">7476969</pub-id></citation></ref><ref id="gke653c40"><label>40.</label><citation citation-type="journal"><name><surname>Rochette-Egly</surname><given-names>C.</given-names></name>, Adam,S., Rossignol,M., Egly,J.M. and Chambon,P. (1997) Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. <source>Cell</source>, <volume>90</volume>, <fpage>97</fpage>&#x02013;<lpage>107</lpage>.<pub-id pub-id-type="pmid">9230306</pub-id></citation></ref><ref id="gke653c41"><label>41.</label><citation citation-type="journal"><name><surname>Taneja</surname><given-names>R.</given-names></name>, Rochette-Egly,C., Plassat,J.L., Penna,L., Gaub,M.P. and Chambon,P. (1997) Phosphorylation of activation functions AF-1 and AF-2 of RAR alpha and RAR gamma is indispensable for differentiation of F9 cells upon retinoic acid and cAMP treatment. <source>EMBO J.</source>, <volume>16</volume>, <fpage>6452</fpage>&#x02013;<lpage>6465</lpage>.<pub-id pub-id-type="pmid">9351827</pub-id></citation></ref><ref id="gke653c42"><label>42.</label><citation citation-type="journal"><name><surname>Delmotte</surname><given-names>M.H.</given-names></name>, Tahayato,A., Formstecher,P. and Lefebvre,P. (1999) Serine 157, a retinoic acid receptor alpha residue phosphorylated by protein kinase C <italic>in vitro</italic>, is involved in RXR.RARalpha heterodimerization and transcriptional activity. <source>J. Biol. Chem.</source>, <volume>274</volume>, <fpage>38225</fpage>&#x02013;<lpage>38231</lpage>.<pub-id pub-id-type="pmid">10608897</pub-id></citation></ref></ref-list></back></article> 